Dr. Clay Siegall is the creator and CEO of Seattle Genetics, a Seattle-based biotech organization that is an expert in the creation of targeted therapy drugs for disease types which may have not seen substantive mortality advancements in decades.
Dr. Clay Siegall has a B.S. in Zoology from the University of Maryland, and a Ph. D in genetics from George Washington School.
Since founding Seattle Genetics in 1998, Dr. Siegall has led the organization to the apex of the therapy industry, expanding the first FDA-approved antibody conjugate, which now has multiple approved signs, as well as formulating a robust pipeline greater than 20 drugs and a string of tactical partnerships with medicine manufacturers including Bayer, Genentech, Pfizer and many more.
What influenced Siegall to start this business?
Siegall was always enthusiastic about medicine and the energy of technology. Siegall first became passionate about tumor treatment while learning zoology in college. A member of his family was suffering and the procedure was brutal. They developed severe anemia at one point and almost perished, not from the cancer, but from the chemotherapy.
So how exactly does Siegall earn a living?
Siegall earns a living by selling his own proprietary drugs. His company’s first FDA-approved antibody drug conjugate, that was actually the first ADC ever before approved by the FDA.
What is the business’s preferred online marketing strategy?
Well, Siegall’s business is one of a kind. The deals they do are usually up to 8 figures. They wine, dine, and spend lots of time in meetings negotiating.
Under Dr. Siegall’s management, Seattle Genetics has launched into into multiple licenses because of its ADC technology, including with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, which have made more than $350 million. Dr. Siegall has led Seattle Genetics’ capital-raising activities, obtaining more than $1.2 billion through general population and private financing.